- Home
- EOI vs REPL Comparison
EOI vs REPL Comparison
Compare EOI & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
EOI
Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | EOI | REPL |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.7M | 721.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EOI | REPL |
|---|---|---|
| Price | $19.84 | $10.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 83.6K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.36 | $2.68 |
| 52 Week High | $18.88 | $14.80 |
Technical Indicators
Market Signals| Indicator | EOI | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 57.76 |
| Support Level | $19.47 | $9.63 |
| Resistance Level | $19.79 | $10.29 |
| Average True Range (ATR) | 0.23 | 0.59 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 71.05 | 35.68 |
Price Performance
Historical ComparisonAbout EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.